• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Atara Biotherapeutics, Inc.

    < Previous 1 2 3 4 Next >
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Announces $36 Million Registered Direct Offering
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Announces $15 Million Registered Direct Offering
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Tickers ATRA
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.